Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery

通过干细胞递送治疗性抗 HIV 嵌合抗原受体

基本信息

  • 批准号:
    9922602
  • 负责人:
  • 金额:
    $ 76.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-16 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY / ABSTRACT While chimeric antigen receptor (CAR) gene therapy was initially tried and abandoned for HIV about 15 years ago, it has recently shown increasing usage and promise for treating cancer. This project revisits this approach for HIV, addressing the key barriers that prevented its success against HIV in the past, including harnessing hematopoietic stem precursor cells (HSPCs) to generate functional and durable CAR T cells in vivo, and generating novel CARs based on broadly neutralizing antibodies (bNAbs) and CAR combinations to prevent viral escape. Our specific aims are: 1. To optimize engraftment of bNAb CAR-transduced HSPCs. CAR T cells would develop entirely in vivo starting from HSPCs, avoiding the caveats of ex vivo T cell expansion and transduction to provide a lifelong self-renewing source. Engraftment will be tested and optimized in a humanized mouse model that recapitulates T cell development (CD34-mice, which are immunodeficient mice reconstituted with blood stem cells from adult human donors). 2. To generate bi-specific combined bNAb CARs to reduce options for HIV-1 escape. Novel CARs will be designed using new bi-specific antibody technologies, creating bi-specific CARs. 3. To select CAR combinations with the best antiviral breadth in vivo. Dual combinations of bi-specific CARs will be challenged in vivo in the CD34- mouse model with artificially diverse HIV-1 quasispecies to determine combinations with effective containment, analogous to combination antiretroviral therapy. These studies will lay the groundwork for successful new approaches to treating HIV infection with CAR gene therapy, which will be a valuable component in future cure strategies.
项目摘要/摘要 虽然嵌合抗原受体(CAR)基因疗法最初在大约15年前被尝试并放弃用于HIV,但它最近显示出越来越多的使用和治疗癌症的前景。该项目重新审视了这种用于HIV的方法,解决了过去阻止其成功对抗HIV的关键障碍,包括利用造血干前体细胞(HSPC)在体内产生功能和持久的CAR T细胞,并基于广泛中和抗体(bNAb)和CAR组合产生新型汽车以防止病毒逃逸。我们的具体目标是: 1.优化bNAb CAR转导的HSPC的植入。CAR T细胞将从HSPC开始完全在体内发育,避免了离体T细胞扩增和转导的注意事项,以提供终身自我更新的来源。将在重现T细胞发育的人源化小鼠模型(CD 34-小鼠,其是用来自成年人供体的血液干细胞重建的免疫缺陷小鼠)中测试和优化移植。 2.产生双特异性组合bNAb汽车以减少HIV-1逃逸的选择。新型汽车将使用新的双特异性抗体技术设计,从而产生双特异性汽车。 3.选择具有最佳体内抗病毒宽度的CAR组合。双特异性汽车的双重组合将在具有人工多样性HIV-1准种的CD 34-小鼠模型中进行体内挑战,以确定具有有效遏制的组合,类似于组合抗逆转录病毒疗法。 这些研究将为CAR基因疗法治疗HIV感染的成功新方法奠定基础,这将是未来治愈策略的重要组成部分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT G KITCHEN其他文献

SCOTT G KITCHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT G KITCHEN', 18)}}的其他基金

Core D -Humanized Mouse and Gene Therapy Core
Core D - 人源化小鼠和基因治疗核心
  • 批准号:
    10458373
  • 财政年份:
    2022
  • 资助金额:
    $ 76.83万
  • 项目类别:
Core D -Humanized Mouse and Gene Therapy Core
Core D - 人源化小鼠和基因治疗核心
  • 批准号:
    10609766
  • 财政年份:
    2022
  • 资助金额:
    $ 76.83万
  • 项目类别:
Enhancing HSPC CAR-mediated immunity in vivo
增强 HSPC CAR 介导的体内免疫
  • 批准号:
    10160820
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Enhancing HSPC CAR-mediated immunity in vivo
增强 HSPC CAR 介导的体内免疫
  • 批准号:
    10614642
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection
明确THC和CBD对HIV感染期间IFN-I介导的炎症和免疫功能障碍的影响和机制
  • 批准号:
    10657439
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection
明确THC和CBD对HIV感染期间IFN-I介导的炎症和免疫功能障碍的影响和机制
  • 批准号:
    10267753
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection
明确THC和CBD对HIV感染期间IFN-I介导的炎症和免疫功能障碍的影响和机制
  • 批准号:
    10447699
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10321545
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:
Enhancing HSPC CAR-mediated immunity in vivo
增强 HSPC CAR 介导的体内免疫
  • 批准号:
    10468651
  • 财政年份:
    2020
  • 资助金额:
    $ 76.83万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 76.83万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了